HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (39) Citing Articles via Google Scholar Google Scholar Articles by Colburn, W. A. Search for Related Content PubMed PubMed Citation Articles by Colburn, W. A.

Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing

From MDS Pharma Services, Phoenix, AZ.

Biomarkers of disease play an important role in medicine and have begun to assume a greater role in drug discovery and development. The challenge for biomarkers is to allow earlier, more robust drug safety and efficacy measurements. Their role in drug development will continue to grow for the foreseeable future. For biomarkers to assume their rightful role, greater understanding of the mechanism of disease progression and therapeutic intervention is needed. In addition, greater understanding of the requirements for biomarker selection and validation, biomarker assay method validation and application, and clinical endpoint validation and application is needed. Biomarkers need to be taken into account while the therapeutic target is still being identified and the concept is being formulated. Biomarkers need to be incorporated into a continuous cycle that takes what is learned from the discovery and development of one series of biomarkers and translates it into the next series of biomarkers. Optimum biomarker development and application will require a team approach because of the multifaceted nature of biomarker selection, validation, and application, using such techniques as pharmacoepidemiology, pharmacogenetics, pharmacogenomics, and functional proteomics; bioanalytical method development and validation; disease process and therapeutic intervention assessments; and pharmacokinetic/pharmacodynamic modeling and simulation to improve and refine drug development. The potential for biomarkers in medicine and drug development will be limited by the least effective component of the processes. The team approach will minimize the potential for the least effective component to be fatal to the rest of the process. As scientific/regulatory foundations for biomarkers in medicine and drug development begin to be established, successes and applications will need to be effectively communicated with all of the stakeholders, including not only internal and external drug developers and regulators but also the medical community, to ensure that biomarkers are totally integrated into drug discovery and development as well as the practice of medicine.

Key Words: Biomarkers • drug discovery and development • pharmacokinetic/pharmacodynamic modeling • surrogate and clinical endpoints

Address for reprints: Deborah L. Keefe, MD, MPH, FCP, P.O. Box 500, New Rochelle, NY 10804-0500.

This article has been cited by other articles:

				C. H. Chau, O. Rixe, H. McLeod, and W. D. Figg Validation of Analytic Methods for Biomarkers Used in Drug Development Clin. Cancer Res., October 1, 2008; 14(19): 5967 - 5976. [Abstract] [Full Text] [PDF]

				K. J Randall and J. R. Foster The Demonstration of Immunohistochemical Biomarkers in Methyl Methacrylate-Embedded Plucked Human Hair Follicles Toxicol Pathol, December 1, 2007; 35(7): 952 - 957. [Abstract] [Full Text] [PDF]

				D. P. Schuster The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease Am. J. Respir. Crit. Care Med., August 1, 2007; 176(3): 224 - 230. [Abstract] [Full Text] [PDF]

				E. M. Fach, L.-A. Garulacan, J. Gao, Q. Xiao, S. M. Storm, Y. P. Dubaquie, S. A. Hefta, and G. J. Opiteck In Vitro Biomarker Discovery for Atherosclerosis by Proteomics Mol. Cell. Proteomics, December 1, 2004; 3(12): 1200 - 1210. [Abstract] [Full Text] [PDF]

				J. W. Zolg and H. Langen How Industry Is Approaching the Search for New Diagnostic Markers and Biomarkers Mol. Cell. Proteomics, April 1, 2004; 3(4): 345 - 354. [Abstract] [Full Text] [PDF]

				E. Floyd and T. M. Mcshane Development and Use of Biomarkers in Oncology Drug Development Toxicol Pathol, January 1, 2004; 32(1_suppl): 106 - 115. [Abstract] [PDF]